Navigation Links
Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
Date:10/10/2007

CALL DATE: Oct. 31, 2007 TIME: 8:30 a.m. Eastern Time HOST: Dr. Candace

Kendle, Chairman and CEO

CINCINNATI, Oct. 10 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL) will conduct a telephone conference call and simultaneous webcast Oct. 31 at 8:30 a.m. Eastern Time to discuss its financial results for the Third Quarter 2007. A question and answer session will follow.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

Webcast Instructions

To access the live webcast, go to http://www.kendle.com or http://www.videonewswire.com/event.asp?id=43011. Instructions for accessing the webcast are provided at both sites. The webcast will be archived at http://www.kendle.com (click on "Investors") shortly after the call for on-demand replay through 5 p.m. Eastern Time on Nov. 30, 2007. Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx.

Conference Call Instructions

To register (RSVP) for the telephone conference call, U.S. and Canadian participants should dial (800) 223-7104. Participants outside North America should dial (706) 645-6519.

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available through 5 p.m. Eastern Time on Nov. 30 by dialing (706) 645-9291 and entering conference ID number 5447273.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations and is the fourth-largest provider of Phase II-IV clinical development services worldwide. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. With the expertise of our more than 3,000 associates worldwide, Kendle has conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.


'/>"/>
SOURCE Kendle
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Biomedical engineering conference invites manufacturers
2. Dispelling the top five myths about attending networking events
3. UW engineering career fair sees highest attendance in four years
4. Visions: Broderick says Wisconsin should be in top third in venture capital
5. Third Wave files countersuit vs. Digene in patent case
6. Third Wave reports net loss of $18.9M for 2006
7. Stratagene to pay Third Wave $10.75M in patent case
8. Third Wave responds to Digene patent lawsuit
9. Third Wave seeks approval of Cystic Fibrosis test
10. Third Wave Technologies to raise $14.9M through private debt
11. Venture capital above $6B for third straight quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):